Translocations of 17q21∼qter in neuroblastoma cell lines infrequently include the topoisomerase IIα gene

Cancer Genetics and Cytogenetics

Volumn 167, Issue 1, 2006, Pages 92-94

  Yoon, K Jin ^a   Danks, Mary K ^a   Ragsdale, Susan T ^b   Valentine, Marcus B ^b   Valentine, Virginia A ^b  

^a Department of Molecular Pharmacology ^*

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE;

CANCER CELL CULTURE; CANCER GROWTH; CHROMOSOME 17Q; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE DELETION; GENE TRANSLOCATION; HUMAN; KARYOTYPE; LETTER; NEUROBLASTOMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; CHROMOSOME 17; COMPARATIVE STUDY; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENETICS; KARYOTYPING; METAPHASE; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; METAPHASE; NEUROBLASTOMA; TRANSLOCATION, GENETIC;

EID: 33646173799     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.11.004     Document Type: Letter

References (18)

1. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 54 (2001) 897-910
2. Tomioka N., Kobayashi H., Kageyama H., Ohira M., Nakamura Y., Sasaki F., Todo S., Nakagawara A., and Kaneko Y. Chromosomes that show partial loss or gain in near-ploid tumors coincide with chromosomes that show whole loss or gain in near-tetraplod tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastoma. Genes Chromosomes Cancer 36 (2003) 139-150
3. Bown N., Cotterill S., Lastowska M., O'Neill S., Pearson A.D.J., Plantaz D., Meddeb M., Gisele D., Brinkschmidt C., Christiansen H., Laureys G., and Speleman A. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340 (1999) 1954-1961
4. Sandler A., Scott D., Azuhata T., Takamizawa S., and O'Dorisio S. The survivin: Fas ratio is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 37 (2002) 507-511
5. Islam A., Kageyama H., Takada N., Nawamoto T., Takayasu H., Isogai E., Ohira M., Hashizume K., Kobayashi H., Kaneko Y., and Nakagawara A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19 (2000) 617-623
6. Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., and Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63 (2003) 1876-1883
7. Zeng G., Gao L., Birkle S., and Yu R.K. Suppression of ganglioside GD3 expression in rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res 60 (2000) 6670-6677
8. Jarvinen T.A.H., Tanner M., Rantanen V., Barlund M., Borg A., Grenman S., and Isola J. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156 (2000) 839-847
9. de Preter K., Speleman F., Combaret V., Lunec J., Laureys G., Eussen B.H.J., Francotte N., Board J., Pearson A.D.J., De Paepe A., Van Roy N., and Vandesompele J. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 15 (2002) 159-166
10. Senchenko V., Liu J., Braga E., Mazurenko N., Loginov W., Seryogin Y., Bazov I., Protopopov A., Kisseljov F., Kashuba V., Lerman M.I., Klein G., and Zabarovsky E.R. Deletion mapping using quantitative real-time PCR identifies two different 3p21.3 regions affected in most cervical carcinomas. Oncogene 22 (2003) 2984-2992
11. Park K., Kim J., Lim S., and Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39 (2003) 631-634
12. Jarvinen T.A.H., Tanner M., Barlund M., Borg A., and Isola J. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26 (1999) 142-150
13. Barlund M., Tirkkonen M., Forozan F., Tanner M.M., Kallioniemi O., and Kallioniemi A. Increased copy number at 17q22∼q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer 20 (1997) 372-376
14. Lastowska M., Cotterill S., Bown N., Cullinane C., Variend S., Lunec J., Strachan T., Pearson A.D.J., and Jackson M.S. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 34 (2002) 428-436
15. Corwell I.G., Okorokov A.L., Cutts S.A., Padget K., Bell M., Milner J., and Austin C.A. Human topoisomerase IIalpha and IIbeta interact with the C-terminal regions of p53. Exp Cell Res 255 (2000) 86-94
16. Kurz E.U., Leader K.B., Kroll D.J., Clark M., and Gieseler F. Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3 epsilon. J Biol Chem 275 (2000) 13948-13954
17. Bhat U.G., Raychaudhuri P., and Beck W.T. Functional interaction between human topoisomerase Iialpha and retinoblastoma protein. Proc Natl Acad Sci USA 96 (1999) 7859-7864
18. Ivanchenko M., and Avramova Z. Interaction of MAR-sequences with nuclear matrix proteins. J Cell Biochem 50 (1992) 190-200